Hanmi’s Rolontis makes USD 10 million in 3 mths
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.02.01 11:20:12
가나다라
0
Hanmi Pharmacuetical’s partner announces last year’s Oct-Dec sales forecast for Rolvedon
Rolvedon is a biodrug developed by Hanmi Pharmacuetical that had been sold since October last year in the US
▲Pic of Rolvedon
Hanmi Pharmaceutical’s partner Spectrum Pharmaceuticals issued a press release announcing that “’Rovedon (Korean brand name: Rolontis)’ that the company had launched in October last year made an estimated sales of KRW 10 million in 3 months.”
Spectrum plans to release details of the results on Rolvedon in its Fiscal Year 2022 Earnings Call that is scheduled for March.
Spectrum received marketing authorization for Rolvedon from the US Food and Drug Administration in September last year, then released Rolvedon in the US in October last year.
Rolontis is a new biodrug that Hanmi Pharmaceutical licensed out to Spectrum Pharmaceuticals in 2012. The drug is indicate
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)